Ethical Dilemmas Contribute To ‘Critical Weaknesses’ In FDA Postmarket Oversight

Ethical challenges are central to persistent “critical weaknesses” in the national system for ensuring drug safety, according to a commentary by former Institute of Medicine members published in the New England Journal of Medicine.

Read more

Posted in Type I Type II Drugs Glucose & Insulin Other News